1,429 Shares in Cencora, Inc. $COR Acquired by Key Financial Inc

Key Financial Inc bought a new position in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,429 shares of the company’s stock, valued at approximately $428,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC increased its holdings in Cencora by 106.7% during the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after acquiring an additional 48 shares during the period. Costello Asset Management INC bought a new stake in Cencora during the 1st quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the 1st quarter worth approximately $39,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Cencora during the 2nd quarter worth approximately $61,000. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on COR. UBS Group upped their target price on shares of Cencora from $350.00 to $380.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Wells Fargo & Company increased their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Evercore ISI set a $340.00 price target on shares of Cencora in a report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $329.55.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $340.74 on Tuesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a one year low of $223.92 and a one year high of $350.46. The company’s fifty day moving average price is $309.14 and its 200-day moving average price is $297.57. The firm has a market capitalization of $66.06 billion, a price-to-earnings ratio of 35.06, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same quarter last year, the firm earned $3.34 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.6%. Cencora’s dividend payout ratio (DPR) is currently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.